Cancer deaths are higher among organ transplant recipients
the ONA take:
Transplant patients receive drugs to prevent rejection of the new organ; however, because those drugs suppress the patient’s immune system, they are more susceptible to cancers many years later.
In particular, transplant recipients in Australia have a high risk of skin cancer because of its high UV levels. Researchers at the University of Adelaide are working on understanding this risk and how cancers can be prevented in this population.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer.
The researchers note, however, that they as of yet have no real way of preventing those cancers from occurring. But in an effort to find a balance between ensuring transplanted organs are not rejected and reducing the risk of cancers in these patients, the research team is conducting further studies to determine what the impact reducing immunosuppressants will have on patients.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|